Literature DB >> 10760032

Cellular immune response to the hepatitis C virus.

B Rehermann1.   

Abstract

Hepatitis C virus (HCV) infection is most often clinically inapparent and rarely associated with symptoms of acute hepatitis. Most patients, however, fail to resolve the acute infection and proceed to develop chronic hepatitis with the risk of liver cirrhosis and hepatocellular carcinoma later in life. Since the kinetics of the earliest events of virus-host interaction are likely to determine the outcome of infection, research has focused on the characterization of the strength and kinetics of the antiviral immune response in different stages of disease. The identification of the immunological correlates of viral clearance is pivotal for the development of vaccines and efficient therapies.

Entities:  

Mesh:

Year:  1999        PMID: 10760032     DOI: 10.1046/j.1365-2893.1999.00008.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

1.  A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection.

Authors:  John A Mengshol; Lucy Golden-Mason; Tomohiro Arikawa; Maxwell Smith; Toshiro Niki; Ryan McWilliams; Jessica A Randall; Rachel McMahan; Michael A Zimmerman; Manu Rangachari; Evgenia Dobrinskikh; Pierre Busson; Stephen J Polyak; Mitsuomi Hirashima; Hugo R Rosen
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

2.  Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients.

Authors:  Walaa R Allam; Ahmed Barakat; Zainab Zakaria; Gehan Galal; Tamer S Abdel-Ghafar; Mohamed El-Tabbakh; Nabiel Mikhail; Imam Waked; Sayed F Abdelwahab
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

3.  A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.

Authors:  A J MacDonald; N A Libri; S Lustigman; S J Barker; M A Whelan; A E Semper; W M Rosenberg
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

Review 4.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.

Authors:  Angela Dolganiuc; Oxana Norkina; Karen Kodys; Donna Catalano; Gennadiy Bakis; Christopher Marshall; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

Review 6.  Emerging concepts in immunity to hepatitis C virus infection.

Authors:  Hugo R Rosen
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

7.  Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.

Authors:  Qi Qiu; Richard Yuan-Hu Wang; Xuanmao Jiao; Bo Jin; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Vaccine       Date:  2008-09-02       Impact factor: 3.641

Review 8.  Interaction of Hepatitis C virus proteins with pattern recognition receptors.

Authors:  Muhammad Imran; Yasir Waheed; Sobia Manzoor; Muhammad Bilal; Waseem Ashraf; Muhammad Ali; Muhammad Ashraf
Journal:  Virol J       Date:  2012-06-22       Impact factor: 4.099

9.  Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.

Authors:  Babs E Verstrepen; Erik Depla; Christine S Rollier; Gwenny Mares; Joost A R Drexhage; Sofie Priem; Ernst J Verschoor; Gerrit Koopman; Christelle Granier; Marlène Dreux; François L Cosset; Geert Maertens; Jonathan L Heeney
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

10.  The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance.

Authors:  Tigran K Davtyan; David A Poghosyan; Anna G Sukiasyan; Michael D Grant
Journal:  J Inflamm (Lond)       Date:  2013-04-05       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.